MedTrace Logo

Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis

NCT01375868 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2019-01-09

No results posted yet for this study

Summary

Vaccines against human papillomaviruses are now commercially available. One of the commercial vaccine contains antigens of both LR HPV types which cause virtually all cases of RRP. Clinical trials have documented the safety and immunogenicity of this vaccine as well as its effectiveness in prevention of incident and persistent infection of the vaccinal types as well as a development of lesions caused by these types. After vaccination the antibodies level increases dramatically and the high levels of antibodies are present in the blood still after 6 years. Furthermore, the neutralization antibodies to the vaccinal antigens have been detected in the cervical mucus of vaccinated women. The preliminary data are now available showing the presence of HPV-specific antibodies in the oral cavity in women after vaccination. The level of antibodies has been dependent on time since vaccination.

Conditions

  • Squamous Papilloma of the Larynx

Interventions

BIOLOGICAL

Silgard

vaccination with tetravalent antiviral vaccine

Sponsors & Collaborators

  • Medical Healthcom Prague

    collaborator UNKNOWN

  • Na Homolce Hospital

    collaborator OTHER

  • Ruth Tachezy, PhD.

    lead OTHER

Principal Investigators

  • Ruth Tachezy, PhD. · Institute of Hematology and Blood Transfusion

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01375868 on ClinicalTrials.gov